Menu
As a key event in the cancer therapeutics calendar, the ENA 2024 Symposium focuses on preclinical and early-phase clinical studies, offering a platform for intense scientific exchange on the most recent advancements in drug development, target selection, and translational research. The meeting is a hub for innovation, attracting pharmaceutical leaders, academics, and scientists from around the world, all dedicated to accelerating progress in cancer treatment.
Hawk Biosystems is pleased to announce our participation in the prestigious 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place from October 23-25, 2024, at the CCIB in Barcelona. This event brings together leading minds in academia, industry, and drug development to discuss cutting-edge research in molecular biology and drug innovation.
Hawk Biosystems will contribute to this vibrant discussion through our poster presentation on the abstract titled: “Beyond PD-L1: Unraveling the Enigma of Immunotherapy Response in PD-L1 Negative (<1%) NSCLC Patients through Quantification of PD-1/PD-L1 Engagement in the Tumour Microenvironment.”
Cristina Cacho, Scientific Officer and Elena Castellano, Research Partnerships will be presenting the poster and we are excited to share these significant findings with the global scientific community and engage in discussions on how molecular insights like these can shape the future of immuno-oncology and cancer treatment.
For more information about our work or to schedule a meeting with our team during the symposium, please contact us
Stay connected
Subscribe to the HAWK Biosystems newsletter and don’t miss any news about our company, our products, events and much more.